. 2023 Jul 5;15(7):1893. doi: 10.3390/pharmaceutics15071893

Table 5.

Antimicrobial exopolysaccharides produced by Bacillus licheniformis.

Substance(s) Specific/Unspecific Name	Producing Strain	Molecular Mass	Activity Assay	Reference
Levan (fructan)	B. licheniformis BK1, BK2	~2–100 × 10³ kDa	Staphylococcus aureus	[188]
Levan (fructan)	B. licheniformis BK1, BK2	~2–100 × 10³ kDa	E. coli Pseudomonas aeruginosa	[188]
EPS1	B. licheniformis 24	ND	Vibrio cholerae non-O1	[189]
Bl-EPS	B. licheniformis Dahb1	ND	B. subtilis KT763078.1 B. pumilus Dahb3 HQ693273.1	[106]
Bl-EPS	B. licheniformis Dahb1	ND	P. aeruginosa Dahp1 (HQ400663.1) P. vulgaris Dahp1 (HQ116441.1)	[106]
EPS-T14	B. licheniformis T14	1000 kDa	multiresistant clinical strains: Staphylococcus aureus	[190]
EPS-T14	B. licheniformis T14	1000 kDa	Escherichia coli Klebsiella pneumonia Pseudomonas aeruginosa	[190]
Exopolysaccharide	B. licheniformis SP1	1800 kDa	Escherichia coli PHL628 Pseudomonas fluorescens (only biofilms formation)	[191]

ND—no data. Gram- bacteria are lower the line, and Gram+ bacteria are above the line.